Nykode Therapeutics ASA (NYKD.OL) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Norway · ISIN NO0010714785
Nykode Therapeutics ASA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 8.68 m USD | 0.00 USD |
| Gross profit | 8.68 m USD | – |
| Operating income | -48.33 m USD | -28.59 m USD |
| EBIT | -45.33 m USD | -17.57 m USD |
| Net income | -38.82 m USD | -12.24 m USD |
| Diluted EPS – continuing operations | -0.12 USD | -0.04 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
More stocks
- MAXCYTE, INC. (MXCT)
- Compagnie Lebon S.A. (ALBON.PA)
- STLLR Gold Inc. (STLR.TO)
- WW INTERNATIONAL, INC. (WW)
- Jyong Biotech Ltd. Ordinary Shares (MENS)
- KLX Energy Services Holdings, Inc. (KLXE)
- K2 Gold Corporation (KTO.V)
- DEEP FISSION, INC. (FISN)
- Solux Co. Ltd (290690.KQ)
- B’IN Live Co Ltd (6625.TW)
- Actinogen Medical Ltd (ACW.AX)
- Maple Gold Mines Ltd (MGM.V)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.